Seven-transmembrane-spanning receptors and heart function

Nature

Volumn 415, Issue 6868, 2002, Pages 206-212

  Rockman, Howard A ^a   Koch, Walter J ^a   Lefkowitz, Robert J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MEMBRANES; CARDIOLOGY; DISEASES; MOLECULES;

CARDIAC RECEPTOR;

BIOLOGICAL ORGANS;

G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; HEART RECEPTOR; HORMONE; NEUROTRANSMITTER; SEVEN TRANSMEMBRANE SPANNING RECEPTOR; UNCLASSIFIED DRUG;

DISEASE;

CARDIOVASCULAR DISEASE; DRUG TARGETING; HEART FUNCTION; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BETA-ADRENERGIC RECEPTOR KINASE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; GTP-BINDING PROTEINS; HEART; HEART DISEASES; HUMANS; MICE; PROTEIN CONFORMATION; RECEPTORS, ADRENERGIC; RECEPTORS, CELL SURFACE; RECEPTORS, MUSCARINIC; SIGNAL TRANSDUCTION;

EID: 0037050009     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/415206a     Document Type: Review

References (77)

1. G protein βγ subunits
2. Cytoplasmic signaling pathways that regulate cardiac hypertrophy
3. G protein-coupled receptors. III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization
4. G protein-coupted receptor kinases
5. 2-adrenergic receptor into clathrin-coated pits
6. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex
7. 2 adrenergic receptor-Src protein kinase complexes
8. β-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2
9. Clathrin-coated vesicle formation and protein sorting: An integrated process
10. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds
11. β-arrestin 2: A receptor-regulated MAPK scaffold for the activation of JNK3
12. 2-adrenergic receptor and β-arrestin
13. Stress pathways and heart failure
14. 2-terminal kinase activity in in vivo pressure overload
15. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy
16. Gβγ-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy
17. Mechanism of β-adrenergic receptor desensitization in cardiac hypertrophy is increased β-adrenergic receptor kinase
18. The α1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy
19. Signaling in myocardial hypertrophy: Life after calcineurin?
20. γ overexpression induces cardiac contractile failure in mice
21. 1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block
22. 2-terminal kinases
23. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy
24. γ interface to inhibit in vivo pressure overload myocardial hypertrophy
25. Wall stress and patterns of hypertrophy in the human left ventricle
26. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study
27. Genetic alterations that inhibit in vivo pressure overload hypertrophy prevent cardiac dysfunction despite increased wall stress
28. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure
29. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
30. Why does the myocardium fail? Insights from basic science
31. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
32. Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart
33. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart
34. 2-adrenergic receptor to different G proteins by protein kinase A
35. 2-adrenergic signaling in adult mouse cardiac myocytes
36. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor
37. 1-adrenoceptor gene variations: A role in idiopathic dilated cardiomyopathy?
38. 2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure
39. 2-adrenergic receptor determine exercise capacity in patients with heart failure
40. Shattuck lecture - Medical and societal consequences of the human genome project
41. The effect of β-adrenergic blockade on patterns of urinary sodium excretion. Studies in normal subjects and in patients with heart disease
42. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
43. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CP/XL randomised intervention trial in congestive heart failure (MER1T-HF)
44. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
45. Effect of carvedilol on survival in severe chronic heart failure
46. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
47. Cellular and functional defects in a mouse model of heart failure
48. Functional consequences of altering myocardial adrenergic receptor signaling
49. 1-adrenergic receptor transgenic mice
50. 2-adrenergic receptor
51. 2-adrenergic receptor overexpression in mouse hearts: Critical role for expression level
52. Physiological consequences of β-adrenergic receptor disruption
53. 2 adrenergic receptor gene
54. 2-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein
55. γ-overexpressing mice
56. Expression of a β-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice
57. Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy
58. Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer
59. 2-adrenergic receptor gene delivery
60. 2-adrenergic receptor in the heart: Prospects for molecular ventricular assistance
61. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy
62. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy
63. Cardiac function in mice overexpressing the β-adrenergic receptor kinase or a β-ARK inhibitor
64. Essential role of β-adrenergic receptor kinase 1 in cardiac development and function
65. Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice
66. Control of myocardial contractile function by the level of β-adrenergic receptor kinase 1 in gene-targeted mice
67. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure
68. Defective β-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression
69. Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene
70. Cardiac β ARK1 inhibition prolongs survival and augments β-blocker therapy in a mouse model of severe heart failure
71. Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction
72. In vivo ventricular gene delivery of a β-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction
73. Agonist-dependent recruitment of phosphoinositide 3-kinase to the membrane by β-adrenergic receptor Kinase 1. A role in receptor sequestration
74. Xamoterol in severe heart failure
75. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by β-adrenergic receptor stimulation and blockade
76. Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure